vimarsana.com

Latest Breaking News On - Bivictrix therapeutics - Page 4 : vimarsana.com

BiVictriX says latest preclincial leukaemia data could accelerate progress

BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) said its Bi-Cygni antibody-drug conjugate, BVX001, has shown a 126% increase in survival rates in a.

Bivictrix says BVX001 increases survival rates by more than double

Bivictrix Therapeutics PLC on Thursday said its Bi-Cygni antibody-drug conjugate, BVX001, showed survival rates more than doubled in a pre-clinical model of acute myeloid leukaemia. The.

BiVictriX posts promising preclinical data on leukaemia candidate

Biotechnology company BiVictriX Therapeutics updated the market on the pre-clinical evaluation of BVX001 on Thursday - its first-in-class ‘Bi-Cygni’ antibody drug conjugate (ADC) developed for the potential treatment of acute myeloid leukaemia (AML).

BiVictriX Therapeutics appoints combined CFO/CBO to boost out-licensing efforts

BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) incoming chief financial officer and chief business officer Adrian Howd speaks to Thomas Warner from.

BiVictriX names Howd CFO and chief business officer

BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) has named Adrian Howd as its new chief financial officer (CFO) and chief business officer (CBO). Howd will.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.